ROC-based methods for meta-analysis of prognosis studies

Satoshi Hattori

Department of Biomedical Statistics, Osaka University, Japan

Collaborators:

Xiao-Hua Zhou, Yi Zhou (Peking U), Ao Huang (Goettingen U)

"Recent Advances in Meta-Analysis: Methods and Software" Symposium, 23Aug2023, UMG Goettingen

Outline

To outline our recent developments of time-dependent Summary ROC-based methods for meta-analysis (MA) of prognosis studies with a survival outcome

- 1. Motivating examples
- Brief review of summary ROC (SROC) for diagnosis(binary) MA
 - Bivariate Gaussian model
 - Bivariate binomial model
- 3. Time-dependent SROC for prognosis MA
- 4. Assessing potential impacts of publication bias (PB)
- 5. Concluding remarks

Motivating examples and Brief review of SROC for diagnosis MA

Prognosis studies

- To evaluate usefulness of factors (including biomarkers) in discriminating who will or will not occur an event of interest in future.
- Useful in current clinical practice
 - To understand disease.
 - To seek potential targets to improve future outcome in patients.

Prognosis studies for a continuous biomarker

- We consider MA of prognosis studies for a continuous biomarker with a survival outcome.
- In general, prognosis studies handle any types of outcomes (continuous, binary and survival).
- In this talk, we call a biomarker study with a binary outcome *Diagnosis* study a survival outcome *Prognosis* study

Heterogeneous cut-off value issue in diagnosis/prognosis MA

- Diagnosis/prognosis studies often employ a study-specific (heterogeneous) cut-off value and define high-/lowexpression groups
 - Sensitivity/specificity, diagnosis
 odds ratio (OR) in diagnosis studies
 - Kaplan-Meier estimates of the two groups and hazard ratio (HR)



- Simple aggregation of ORs/HRs with the standard MA is hard to interpret.
- Summary ROC is an appealing tool in diagnosis MA(binary)

Example of diagnosis MA: Troponin data Becattini et al. (Circulation 2007)

- Meta analysis of 20 prognostic studies (1985 patients)
- Troponin I/T in acute pulmonary embolism
- Endpoint: short-term death (binary)
- Two troponins have different scales.
- Cut-off values vary across studies:
 - Troponin I: 0.06 2.0, Troponin T: 0.01 0.1
- Combined OR (Mixed-effect model):
 - Troponin I: OR=4.01 (95% CI: 2.23 7.23)
 - TroponinT: OR=7.95 (95% CI: 3.79 16.65)
- Hard to interpret and compare these ORs.

Summary receiver operating characteristics (SROC) for diagnosis MA: data structure

S: No of published studies D: binary outcome M: biomarker $c^{(s)}$: cut-off value $X=I(c^{(s)} \le M < \infty)$:high/low-expression

The following frequencies are supposed to be observed for the sth study (s = 1,2,...S) $\frac{D = 0 \quad D = 1}{X = 0: 0 \le M < c^{(s)} \quad N_{00}^{(s)} \quad N_{01}^{(s)} \quad n_{0+}^{(s)} \\ X = 1: c^{(s)} \le M < \infty \quad N_{10}^{(s)} \quad N_{11}^{(s)} \quad n_{1+}^{(s)} \\ \hline n_{+0}^{(s)} \quad n_{+1}^{(s)} \quad n_{+1}^{(s)} \\ \hline n_{+0}^{(s)} \quad n_{+1}^{(s)} \quad n_{-1}^{(s)} \\ \hline n_{+0}^{(s)} \quad n_{+1}^{(s)} \\ \hline n_{+0}^{(s)} \quad n_{+1}^{(s)} \\ \hline n_{+1}^{(s)} \quad n_{+1}^{(s)} \quad n_{+1}^{(s)} \\ \hline n_{+1}^{(s)} \quad n_{+1}^{(s)} \quad n_{+1}^{(s)} \\ \hline n_{+1}^{(s)} \quad n_{+1}^{(s)} \quad n_{+1}^{(s)} \quad n_{+1}^{(s)} \quad n_{+1}^{(s)} \\ \hline n_{+1}^{(s)} \quad n_{+1}^{(s)}$

SROC for diagnosis MA: idea

- Due to heterogeneous cut-off values over studies, sensitivity and specificity are likely to be negatively correlated.
- Model the association between sensitivity and specificity with bivariate mixed-effect models
 - Bivariate Gaussian model
 - Bivariate binomial model
- Express sensitivity as a function of specificity (SROC curve)

Bivariate Gaussian model for diagnosis MA

Model the joint distribution of empirical sensitivity and specificity based on asymptotic normal approximation

$$\begin{aligned} \hat{\mu}_{sen}^{(s)} &= \operatorname{logit}(s\hat{e}n^{(s)}) = \operatorname{logit}\left(\frac{N_{11}^{(s)}}{n_{+1}^{(s)}}\right) & \text{Diagonal matrix} \\ \hat{\mu}_{spe}^{(s)} &= \operatorname{logit}(s\hat{p}e^{(s)}) = \operatorname{logit}\left(\frac{N_{00}^{(s)}}{n_{+0}^{(s)}}\right) \\ \begin{pmatrix} \hat{\mu}_{sen}^{(s)} \\ \hat{\mu}_{spe}^{(s)} \end{pmatrix} &\sim N\left(\begin{pmatrix} \mu_{sen}^{(s)} \\ \mu_{spe}^{(s)} \end{pmatrix}, U^{(s)} \end{pmatrix}, \quad U^{(s)}(t) = \begin{pmatrix} \hat{s}_{sen}^{(s)}, 0 \\ 0, \hat{s}_{spe}^{(s)} \end{pmatrix} \\ \begin{pmatrix} \mu_{sen}^{(s)} \\ \mu_{spe}^{(s)} \end{pmatrix} &\sim N\left(\begin{pmatrix} \mu_{sen} \\ \mu_{spe} \end{pmatrix}, \Sigma\right), \quad \Sigma = \begin{pmatrix} \tau_{sen,spe}^{2}, \tau_{sen,spe} \\ \tau_{sen,spe}, \tau_{spe}^{2} \end{pmatrix} \\ & \text{ML or REML estimation} \\ \text{is applicable} \end{aligned}$$

SROC curve: $E\left(\mu_{sen}^{(s)}|\mu_{spe}^{(s)}\right)$

Reitsma et al. (2005, J Clinical Epidemiology)

Bivariate binomial model for diagnosis MA

Model the joint distribution of the bivariate binomial random variables.

$$\begin{aligned} \pi_{1}^{(s)} &= TPR^{(s)} = s\hat{e}n^{(s)} = P(X = 1|D = 1) \\ \pi_{0}^{(s)} &= FPR^{(s)} = 1 - s\hat{p}e^{(s)} = P(X = 1|D = 0) \\ N_{1d}^{(s)} &\sim Bin\left(n_{+d}^{(s)}, \pi_{d}^{(s)}\right), \qquad \log it\left(\pi_{d}^{(s)}\right) = \frac{\theta + \theta^{(s)} + (\alpha + \alpha^{(s)})Z_{d}^{(s)}}{\exp\left(\beta Z_{d}^{(s)}\right)}, \quad d=0,1 \\ Z_{d}^{(s)} &= -1/2(d = 0), \qquad = 1/2(d = 1) \\ \theta^{(s)} &\sim N(0, \sigma_{\theta}^{2}), \alpha^{(s)} \sim N(0, \sigma_{\alpha}^{2}), \theta^{(s)} \perp \alpha^{(s)} \end{aligned}$$

MCMC (Rutter and Gastnis 2001, SiM) REML (Macaskill 2004, J. Clinical Epidemiology)

SROC curve:

$$TPR = \frac{1}{1 + \exp\{-(\alpha \exp(-0.5\beta) + \operatorname{logit}(FPR) \exp(-\beta))\}}$$

SROC with bivariate binomial model: Troponin data



Hattori and Zhou (2016, SiM)

12

Time-dependent SROC for prognosis MA

Example of prognosis MA: Ki-67 data De Azambuja et al. (British J Cancer 2007)

- Meta-analysis of 38 prognostic studies with 9472 subjects.
- Ki-67 in early breast cancer
 - Proportion of expressed cells in tumor (0-1)
 - Proliferation
 - Important role in discriminating between Luminal A and B
- Endpoint: OS
- Standard meta-analysis techniques were applied:
 - Random-effect model: HR=1.93 (95%CI 1.74-2.14)
- Cut-off values are heterogeneous (0.035 0.32)
 ⇒The above results seem to be difficult to interpret.

Time-dependent Summary ROC curve

Data: Kaplan-Meier plot



MA version of time-dependent ROC (Heagerty et al. 2000, Biometrics)

Combescure et al. (2016, SMMR) -Spline-based joint model to KM and biomarker dist.

> Time-dependent (summary) ROC curve

Hattori and Zhou (2016, SiM) -Natural extension of sROC for diagnostic studies (binary outcome) -Bivariate Gaussian model -Bivariate binomial model

Time-dependent SROC for prognosis MA

Suppose we are interested in estimating SROC at t-year.

Evaluate capacity of the biomarker M to "diagnose" t-year survivor

T: survival time $D=I(T \le t)$: unobservable due to censoring



Bivariate Gaussian model for prognosis MA

Idea: construct time-dependent sensitivity and specificity with KMs.

$$sen^{(s)}(t) = P(M \ge c^{(s)}|T \le t) = \frac{\{1 - S_1^{(s)}(t)\}q_1^{(s)}}{\{1 - S_1^{(s)}(t)\}q_1^{(s)} + \{1 - S_0^{(s)}(t)\}q_0^{(s)}}$$
$$spe^{(s)}(t) = P(M < c^{(s)}|T > t) = \frac{S_0^{(s)}(t)q_0^{(s)}}{S_1^{(s)}(t)q_1^{(s)} + S_0^{(s)}(t)q_0^{(s)}}$$
$$q_1^{(s)} = P(M \ge c^{(s)}), q_0^{(s)} = P(M < c^{(s)})$$

Consider empirical versions: $s\hat{e}n^{(s)}(t), s\hat{p}e^{(s)}$

Bivariate Gaussian model for prognosis MA

No longer diagonal

But it is estimable with KMs $\hat{\mu}_{sen}^{(s)}(t) = \operatorname{logit}\left(s\hat{e}n(v^{(s)}, t)\right)$ $\hat{\mu}_{spe}^{(s)}(t) = \operatorname{logit}\left(s\hat{p}e(v^{(s)}, t)\right)$ $\begin{pmatrix} \hat{\mu}_{sen}^{(s)}(t) \\ \hat{\mu}_{spe}^{(s)}(t) \end{pmatrix} \sim N \begin{pmatrix} \begin{pmatrix} \mu_{sen}^{(s)}(t) \\ \mu_{spe}^{(s)} \end{pmatrix}(t), U^{(s)}(t) \end{pmatrix}, \quad U^{(s)}(t) = \begin{pmatrix} \hat{s}_{sen}^{(s)}(t), \quad \hat{s}_{sen,spe}^{(s)}(t) \\ \hat{s}_{sen,spe}^{(s)}(t), \quad \hat{s}_{spe}^{(s)}(t) \end{pmatrix}$ $\begin{pmatrix} \mu_{sen}^{(s)}(t) \\ \mu_{sen}^{(s)}(t) \end{pmatrix} \sim N\left(\begin{pmatrix} \mu_{sen}(t) \\ \mu_{sne}(t) \end{pmatrix}, \Sigma(t) \right), \qquad \Sigma(t) = \begin{pmatrix} \tau_{sen}^2(t), & \tau_{sen,spe}(t) \\ \tau_{sen,sne}(t), & \tau_{sne}^2(t) \end{pmatrix}$

SROC curve:
$$E\left(\mu_{sen}^{(s)}(t)|\mu_{spe}^{(s)}(t)\right)$$

Bivariate binomial model for prognosis MA

If missing cell frequencies are successfully imputed, the standard bivariate binomial model for diagnosis MA is applicable.



Missing due to censoring

Problem: how to impute the cell frequencies?

Bivariate binomial model for prognosis MA

Multiple imputation (MI):

Sample missing observations from conditional distribution given observed:

$$\mathbf{Y}_{mis} \sim f(\mathbf{Y}_{mis} | \mathbf{Y}_{obs})$$

Rubin's variance formula is justified for these samples.

Bivariate binomial model for prognosis MA:



Bivariate binomial model for prognosis MA: MI

$$\begin{aligned} Step 1: S_{z}^{(s)}(t) \left| \hat{S}_{z}^{(s)}(t) \sim f\left(S_{z}^{(s)}(t) | \hat{S}_{z}^{(s)}(t)\right) \\ & \hat{S}_{z}^{(s)}(t) \sim N\left(S_{z}^{(s)}(t), \frac{\sigma_{z}^{2}(t)}{n_{z}^{(s)}}\right) \qquad \sigma_{z}^{2}(t): \text{ Greenwood variance} \\ & S_{z}^{(s)}(t) | \hat{S}_{z}^{(s)}(t) \sim N\left(\hat{S}_{z}^{(s)}(t), \frac{\sigma_{z}^{2}(t)}{n_{z}^{(s)}}\right) \text{ with a vague prior} \\ \\ Step 2: \hat{p}_{z}^{(s)} \left| \hat{S}_{z}^{(s)}(t), S_{z}^{(s)}(t) \sim f\left(\hat{p}_{z}^{(s)} | \hat{S}_{z}^{(s)}(t), S_{z}^{(s)}(t)\right) \\ & \left(\hat{p}_{z}^{(s)} \right) \sim N\left(\left(\frac{S_{z}^{(s)}(t)}{S_{z}^{(s)}(t)}, \frac{1}{n_{z+}^{(s)}} \left(\frac{u_{z}^{(s)}(t), u_{z}^{(s)}(t)}{u_{z}^{(s)}(t), \sigma_{z}^{2}(t)} \right) \right) \\ & u_{z}^{(s)}(t) = S_{z}^{(s)}(t) \left\{ 1 - S_{z}^{(s)}(t) \right\} : \text{bionomial variance} \end{aligned}$$

 $\hat{p}_z^{(s)}|\hat{S}_z^{(s)}(t), S_z^{(s)}(t) \sim normal$

Application to Ki-67 data





Assessing potential impacts of publication bias (PB)

Publication bias (PB) in diagnosis/prognosis MA

- Publication bias is a serious concern in validity of MA.
- For MA of intervention studies, various methods for PB
 - graphical methods
 - sensitivity analysis
- Simple graphical procedures are hard to apply to multivariate MA.
- Sensitivity analysis method is an objective framework to address PB.

Sensitivity analysis methods for MA of intervention studies

Various sensitivity analysis methods are available

Parametric approach:

- Heckman-type selection function (Copas 1999, JRSS-C; Copas and Shi 2000, Biostatistics)
- t-statistic based selection function (Copas 2013, JRSS-C)

Nonparametric approach:

Nonparametric worst-case bound (Copas and Jackson 2004, Biometrics)

Sensitivity analysis methods for diagnosis MA

Several extensions have been made.

Bivariate Gaussian model;

- Piao et al. (2019, SMMR): Heckman-type
- Li et al. (2021, Metrika): Heckman-type
- Zhou, Huang and Hattori (2023, SiM): t-statistic type
- Zhou, Huang and Hattori (in preparation): nonparametric worst-case bound

Bivariate binomial model;

- Hattori and Zhou (2018, SiM): Heckman-type

Sensitivity analysis methods for prognosis MA

Zhou, Huang and Hattori (arXiv:2305.19741 [stat.ME])

Results of the logrank test would be responsible for publication.

Selection function: $P(pubished|data) = \Phi(\alpha + \beta \times Z)$ Z: the logrank test statistics



- Estimate time-dependent SROC under this selection process via (conditional) MLE
- Evaluate how the estimates may change as the marginal publication probability
 p=P(pubished) decreases.

Sensitivity analysis methods for prognosis MA

Application to Ki-67 data



Concluding remarks

We reviewed recent methodological development of prognosis MA

- Meta-analytic version of time-dependent ROC
- Meta-analytic C-index for a survival outcome (Hattori and Zhou 2022, SiM)
- Software is under development and will be opened.

Thanks so much for your kind attention!